ALXO Alx Oncology Holdings Inc

Price (delayed)

$16.25

Market cap

$809.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.57

Enterprise value

$799.55M

ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ...

Highlights
The quick ratio has dropped by 55% since the previous quarter and by 52% year-on-year
Alx Oncology Holdings's equity has decreased by 41% YoY and by 21% QoQ

Key stats

What are the main financial stats of ALXO
Market
Shares outstanding
49.82M
Market cap
$809.56M
Enterprise value
$799.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$144.83M
EBITDA
-$144.09M
Free cash flow
-$112.87M
Per share
EPS
-$3.57
Free cash flow per share
-$2.74
Book value per share
$4.1
Revenue per share
$0
TBVPS
$5.35
Balance sheet
Total assets
$220.11M
Total liabilities
$51.36M
Debt
$9.58M
Equity
$168.75M
Working capital
$163.93M
Liquidity
Debt to equity
0.06
Current ratio
5.66
Quick ratio
5.41
Net debt/EBITDA
0.07
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.6%
Return on equity
-66%
Return on invested capital
-71%
Return on capital employed
-78.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALXO stock price

How has the Alx Oncology Holdings stock price performed over time
Intraday
2.52%
1 week
14.76%
1 month
22.09%
1 year
112.7%
YTD
9.13%
QTD
9.13%

Financial performance

How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$154.47M
Net income
-$146.04M
Gross margin
N/A
Net margin
N/A
ALXO's operating income is down by 25% YoY and by 12% QoQ
ALXO's net income is down by 20% year-on-year and by 12% since the previous quarter

Growth

What is Alx Oncology Holdings's growth rate over time

Valuation

What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
3.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 20% year-on-year and by 12% since the previous quarter
Alx Oncology Holdings's equity has decreased by 41% YoY and by 21% QoQ

Efficiency

How efficient is Alx Oncology Holdings business performance
ALXO's return on equity has dropped by 78% year-on-year and by 27% since the previous quarter
The return on assets has dropped by 62% year-on-year and by 22% since the previous quarter
ALXO's return on invested capital is down by 21% since the previous quarter

Dividends

What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALXO.

Financial health

How did Alx Oncology Holdings financials performed over time
The total liabilities has surged by 67% year-on-year and by 54% since the previous quarter
Alx Oncology Holdings's current ratio has plunged by 55% from the previous quarter and by 51% YoY
The debt is 94% smaller than the equity
Alx Oncology Holdings's debt to equity has soared by 50% from the previous quarter
Alx Oncology Holdings's equity has decreased by 41% YoY and by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.